AbbVie Inc. $ABBV Holdings Boosted by Lbmc Investment Advisors LLC

Lbmc Investment Advisors LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 90.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,845 shares of the company’s stock after purchasing an additional 2,773 shares during the quarter. Lbmc Investment Advisors LLC’s holdings in AbbVie were worth $1,353,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie during the 2nd quarter worth $26,000. TD Capital Management LLC raised its stake in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new position in AbbVie in the 2nd quarter valued at about $28,000. Finally, Financial Gravity Companies Inc. acquired a new position in AbbVie during the 2nd quarter valued at about $36,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 0.3%

Shares of AbbVie stock opened at $224.32 on Thursday. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $396.47 billion, a PE ratio of 169.94, a price-to-earnings-growth ratio of 1.27 and a beta of 0.36. The stock’s fifty day moving average is $226.87 and its 200-day moving average is $210.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the business posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Morgan Stanley upped their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Citigroup lowered their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Finally, Bank of America raised their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $245.84.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.